AAA
TARS icon

Affinity Asset Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Affinity Asset Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-125,000
Closed -$7.43M – 121
2025
Q3 		$7.43M Buy
+125,000
New +$6.15M 0.65% 43

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Affinity Asset Advisors's TARS Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Tarsus Pharmaceuticals (TARS) in Q4 2025, closing a stake of 125,000 shares — an estimated $7.43M sold.

Affinity Asset Advisors first reported a position in TARS in Q3 2025 and held it in 1 quarter. The position peaked at $7.43M in Q3 2025. 246 funds tracked by Wall St. Rank hold TARS as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Tarsus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 125,000 Tarsus Pharmaceuticals shares in Q4 2025, an estimated $7.43M.
  • Affinity Asset Advisors first reported a position in Tarsus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Affinity Asset Advisors's Tarsus Pharmaceuticals position peaked at $7.43M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.